Last updated: 2026-09-30 08:34:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
CalciMedica, Inc. (CALC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.64, with a market capitalization of $11.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $36.00. This page covers its latest market performance, valuation, price trends and company information.
$11.47M | |
$1.64 | |
$2,807.00 | |
$1.58 | |
$1.61 | |
168.00 | |
77.77K | |
-- | |
$36.00 | |
$1.58 | |
-- | |
-- |
CalciMedica, Inc. (CALC) is trading at $1.64 in pre-market trading as of 2026-09-30 08:03:00, up 1.86% ($0.03) from the previous close of $1.61
Pre-market trading shows how investors are pricing CALC before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, CalciMedica, Inc. (CALC) moved from $1.86 to $1.64, representing a decline of 11.83% ($0.22).
The stock traded between $1.58 and $1.98 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 54.75 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.2%
CALC is currently trading at $1.64, placing it 0.2% of the way from its 52-week low of $1.58 to its 52-week high of $36.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CalciMedica, Inc. (CALC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.